Some years ago, billionaire Randal J. Kirk took over a relatively unknown biopharma company called Intrexon (NYSE:XON), invested hundreds of millions of dollars of his own money into it, and gradually built it into an engineered biology conglomerate valued at over $3 billion today. It can be a little difficult to keep track of developments, especially with business segments and R&D projects that span therapeutics, public health, transportation fuels, industrial chemicals, agriculture, and more.
